A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
20 participants are expected to be enrolled for this open，Single-armed clinical trial to
evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients
with relapsed/refractory bone and soft tissue tumors.